{"slug":"trialist","tag":"trialist","variants":["trialist"],"description":"People known for designing and leading clinical trials.","count":142,"kinds":{"person":142},"related":[{"slug":"immunotherapy","tag":"immunotherapy","shared":23},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":22},{"slug":"surgery","tag":"surgery","shared":14},{"slug":"breast","tag":"breast","shared":12},{"slug":"sarcoma","tag":"sarcoma","shared":11},{"slug":"prostate","tag":"prostate","shared":10},{"slug":"brain","tag":"brain","shared":9},{"slug":"melanoma","tag":"melanoma","shared":8},{"slug":"gastric","tag":"gastric","shared":7},{"slug":"gynaecological","tag":"gynaecological","shared":7},{"slug":"hcc","tag":"hcc","shared":7},{"slug":"leukaemia","tag":"leukaemia","shared":7}],"records":[{"id":"richard-finn","kind":"person","name":"Richard S. Finn","route":"/people/richard-finn/","tldr":"Led PALOMA-2, which made palbociclib a first-line breast cancer drug, and IMbrave150, which made immunotherapy the standard for liver cancer."},{"id":"gabriel-hortobagyi","kind":"person","name":"Gabriel N. Hortobagyi","route":"/people/gabriel-hortobagyi/","tldr":"Breast oncologist who led MONALEESA-2, the first CDK4/6 trial to show an overall survival gain in first-line HR-positive disease."},{"id":"stephen-johnston","kind":"person","name":"Stephen Johnston","route":"/people/stephen-johnston/","tldr":"Chief investigator of monarchE, the trial that added abemaciclib to adjuvant endocrine therapy for high-risk early breast cancer."},{"id":"sandra-swain","kind":"person","name":"Sandra M. Swain","route":"/people/sandra-swain/","tldr":"Led CLEOPATRA, which showed dual HER2 blockade with pertuzumab gives an unprecedented 16-month survival gain in metastatic disease."},{"id":"peter-schmid","kind":"person","name":"Peter Schmid","route":"/people/peter-schmid/","tldr":"Led KEYNOTE-522 and IMpassion130, the trials that brought immunotherapy into triple-negative breast cancer."},{"id":"aditya-bardia","kind":"person","name":"Aditya Bardia","route":"/people/aditya-bardia/","tldr":"Led ASCENT, the trial that made sacituzumab govitecan the first ADC for triple-negative breast cancer, and the EMERALD trial of elacestrant."},{"id":"martin-reck","kind":"person","name":"Martin Reck","route":"/people/martin-reck/","tldr":"Led KEYNOTE-024, the trial that made pembrolizumab alone first-line therapy for PD-L1-high lung cancer."},{"id":"thierry-conroy","kind":"person","name":"Thierry Conroy","route":"/people/thierry-conroy/","tldr":"Led the FOLFIRINOX trials that gave pancreatic cancer its most active chemotherapy in both metastatic and adjuvant settings."},{"id":"zev-wainberg","kind":"person","name":"Zev A. Wainberg","route":"/people/zev-wainberg/","tldr":"Led NAPOLI 3, the trial that made NALIRIFOX a first-line option for metastatic pancreatic cancer."},{"id":"josep-llovet","kind":"person","name":"Josep M. Llovet","route":"/people/josep-llovet/","tldr":"Led SHARP, which made sorafenib the first systemic therapy for liver cancer, and created the BCLC staging system."},{"id":"masatoshi-kudo","kind":"person","name":"Masatoshi Kudo","route":"/people/masatoshi-kudo/","tldr":"Japanese hepatologist who led REFLECT, the trial that made lenvatinib a first-line option for liver cancer."},{"id":"ghassan-abou-alfa","kind":"person","name":"Ghassan K. Abou-Alfa","route":"/people/ghassan-abou-alfa/","tldr":"Led HIMALAYA and ClarIDHy, which gave liver cancer a dual-immunotherapy option and biliary cancer its first targeted drug."},{"id":"juan-valle","kind":"person","name":"Juan W. Valle","route":"/people/juan-valle/","tldr":"Led ABC-02, which made gemcitabine plus cisplatin the global standard for biliary cancer, and co-led TOPAZ-1."},{"id":"christopher-sweeney","kind":"person","name":"Christopher J. Sweeney","route":"/people/christopher-sweeney/","tldr":"Led CHAARTED, which showed adding docetaxel to hormone therapy extends survival in newly metastatic prostate cancer."},{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","route":"/people/oliver-sartor/","tldr":"Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer."},{"id":"matthew-smith","kind":"person","name":"Matthew R. Smith","route":"/people/matthew-smith/","tldr":"Led ARASENS and SPARTAN, trials that established darolutamide triplet therapy and apalutamide for prostate cancer."},{"id":"kim-chi","kind":"person","name":"Kim N. Chi","route":"/people/kim-chi/","tldr":"Led TITAN and MAGNITUDE, bringing apalutamide to hormone-sensitive disease and niraparib to HRR-mutant prostate cancer."},{"id":"andrew-armstrong","kind":"person","name":"Andrew J. Armstrong","route":"/people/andrew-armstrong/","tldr":"Led ARCHES, which established enzalutamide with hormone therapy for metastatic hormone-sensitive prostate cancer."},{"id":"thomas-powles","kind":"person","name":"Thomas Powles","route":"/people/thomas-powles/","tldr":"Led EV-302, NIAGARA and IMvigor011, the trials that transformed bladder cancer from chemotherapy-only to ADC, immunotherapy and ctDNA-guided care."},{"id":"robert-motzer","kind":"person","name":"Robert J. Motzer","route":"/people/robert-motzer/","tldr":"The kidney cancer trialist behind sunitinib, CheckMate 214 and CLEAR, three shifts in first-line standard of care."},{"id":"brian-rini","kind":"person","name":"Brian I. Rini","route":"/people/brian-rini/","tldr":"Led KEYNOTE-426, which made pembrolizumab plus axitinib a first-line standard for kidney cancer."},{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/","tldr":"Led SOLO-1 and MIRASOL, which gave ovarian cancer a maintenance PARP inhibitor and its first ADC with a survival benefit."},{"id":"mansoor-raza-mirza","kind":"person","name":"Mansoor Raza Mirza","route":"/people/mansoor-raza-mirza/","tldr":"Led NOVA and RUBY, the trials that established niraparib maintenance in ovarian cancer and dostarlimab in advanced endometrial cancer."},{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","route":"/people/jedd-wolchok/","tldr":"Led CheckMate 067, the trial whose ten-year data showed half of advanced melanoma patients on nivolumab plus ipilimumab are alive."},{"id":"caroline-robert","kind":"person","name":"Caroline Robert","route":"/people/caroline-robert/","tldr":"Led KEYNOTE-006 and COMBI-v, the trials that made pembrolizumab and dabrafenib-trametinib standards in melanoma."},{"id":"william-tap","kind":"person","name":"William D. Tap","route":"/people/william-tap/","tldr":"Sarcoma oncologist who led ANNOUNCE and the pexidartinib trial that produced the first drug for tenosynovial giant cell tumour."},{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/","tldr":"Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours."},{"id":"james-yao","kind":"person","name":"James C. Yao","route":"/people/james-yao/","tldr":"Led the RADIANT trials that made everolimus a standard therapy for pancreatic and other neuroendocrine tumours."},{"id":"courtney-dinardo","kind":"person","name":"Courtney D. DiNardo","route":"/people/courtney-dinardo/","tldr":"Led VIALE-A, which made venetoclax plus azacitidine the standard for older patients with acute myeloid leukaemia."},{"id":"uwe-platzbecker","kind":"person","name":"Uwe Platzbecker","route":"/people/uwe-platzbecker/","tldr":"Led MEDALIST and COMMANDS, which made luspatercept a first-line treatment for anaemia in lower-risk MDS."},{"id":"gilles-salles","kind":"person","name":"Gilles Salles","route":"/people/gilles-salles/","tldr":"Led PRIMA, which established rituximab maintenance in follicular lymphoma, and co-chaired POLARIX in DLBCL."},{"id":"peter-borchmann","kind":"person","name":"Peter Borchmann","route":"/people/peter-borchmann/","tldr":"Leads the German Hodgkin Study Group and HD21, which made BrECADD the most effective and least toxic regimen for advanced Hodgkin lymphoma."},{"id":"jennifer-brown","kind":"person","name":"Jennifer R. Brown","route":"/people/jennifer-brown/","tldr":"Led ALPINE, the first head-to-head trial in which a next-generation BTK inhibitor (zanubrutinib) beat ibrutinib."},{"id":"philippe-moreau","kind":"person","name":"Philippe Moreau","route":"/people/philippe-moreau/","tldr":"Led MajesTEC-1 and CASSIOPEIA, bringing the first bispecific antibody and daratumumab quadruplets to myeloma."},{"id":"thierry-facon","kind":"person","name":"Thierry Facon","route":"/people/thierry-facon/","tldr":"Led MAIA, which made daratumumab-lenalidomide-dexamethasone the standard for older patients with myeloma."},{"id":"meletios-dimopoulos","kind":"person","name":"Meletios A. Dimopoulos","route":"/people/meletios-dimopoulos/","tldr":"Greek haematologist who led POLLUX and CANDOR, two of the pivotal daratumumab combination trials in relapsed myeloma."},{"id":"matthew-hellmann","kind":"person","name":"Matthew D. Hellmann","route":"/people/matthew-hellmann/","tldr":"Lung cancer doctor who was the lead author of CheckMate 227, the trial that showed the immunotherapy pair nivolumab and ipilimumab helps people with advanced lung cancer live longer than chemotherapy alone."},{"id":"keunchil-park","kind":"person","name":"Keunchil Park","route":"/people/keunchil-park/","tldr":"Korean lung cancer specialist who led CHRYSALIS, the first human study of amivantamab, whose exon 20 insertion cohort earned the drug its first approval."},{"id":"alice-shaw","kind":"person","name":"Alice T. Shaw","route":"/people/alice-shaw/","tldr":"Lung cancer doctor whose trials at Massachusetts General Hospital showed that crizotinib works in ROS1-rearranged lung cancer and defined how ALK-positive tumours become resistant to targeted drugs."},{"id":"gregory-riely","kind":"person","name":"Gregory J. Riely","route":"/people/gregory-riely/","tldr":"Lung cancer doctor who led PHAROS, the trial that brought the encorafenib and binimetinib pair to BRAF V600E-mutant lung cancer."},{"id":"paul-paik","kind":"person","name":"Paul K. Paik","route":"/people/paul-paik/","tldr":"Lung cancer doctor who was lead author of VISION, the trial that established tepotinib for lung cancers with MET exon 14 skipping mutations."},{"id":"salah-eddin-al-batran","kind":"person","name":"Salah-Eddin Al-Batran","route":"/people/salah-eddin-al-batran/","tldr":"German oncologist who led FLOT4, the trial that made the FLOT chemotherapy regimen the standard before and after surgery for stomach and oesophago-gastric junction cancer."},{"id":"yuichiro-doki","kind":"person","name":"Yuichiro Doki","route":"/people/yuichiro-doki/","tldr":"Japanese surgeon who was lead author of CheckMate 648, which established nivolumab-based first-line treatment for advanced oesophageal squamous-cell carcinoma."},{"id":"jong-mu-sun","kind":"person","name":"Jong-Mu Sun","route":"/people/jong-mu-sun/","tldr":"Korean oncologist who was lead author of KEYNOTE-590, the trial that added pembrolizumab to first-line chemotherapy for advanced oesophageal cancer."},{"id":"peter-thuss-patience","kind":"person","name":"Peter Thuss-Patience","route":"/people/peter-thuss-patience/","tldr":"Berlin oncologist who led GATSBY, the trial showing that the antibody-drug conjugate T-DM1 did not beat taxane chemotherapy in previously treated HER2-positive stomach cancer."},{"id":"jens-hoeppner","kind":"person","name":"Jens Höppner","route":"/people/jens-hoeppner/","tldr":"German surgeon who led ESOPEC, the trial that compared FLOT chemotherapy with CROSS chemoradiotherapy before surgery for oesophageal adenocarcinoma and found FLOT gave longer survival."},{"id":"hyung-ho-kim","kind":"person","name":"Hyung-Ho Kim","route":"/people/hyung-ho-kim/","tldr":"Korean surgeon who led KLASS-01, the trial that showed keyhole gastrectomy is as safe and effective as open surgery for early stomach cancer."},{"id":"hitoshi-katai","kind":"person","name":"Hitoshi Katai","route":"/people/hitoshi-katai/","tldr":"Japanese surgeon who led JCOG0912, the trial that confirmed laparoscopic gastrectomy is not inferior to open surgery for early stomach cancer."},{"id":"manish-shah","kind":"person","name":"Manish A. Shah","route":"/people/manish-shah/","tldr":"New York oncologist who was lead author of GLOW, one of the two trials that established zolbetuximab, the first drug aimed at claudin 18.2, for stomach cancer."},{"id":"hansjochen-wilke","kind":"person","name":"Hansjochen Wilke","route":"/people/hansjochen-wilke/","tldr":"German oncologist who led RAINBOW, the trial that made ramucirumab plus paclitaxel a standard second-line treatment for advanced stomach cancer."},{"id":"jordi-bruix","kind":"person","name":"Jordi Bruix","route":"/people/jordi-bruix/","tldr":"Barcelona liver specialist who co-created the BCLC staging system used worldwide to decide how liver cancer is treated, and led STORM, which showed adjuvant sorafenib does not help after curative treatment."},{"id":"john-primrose","kind":"person","name":"John N. Primrose","route":"/people/john-primrose/","tldr":"British surgeon who led BILCAP, the trial that made six months of capecitabine the standard after surgery for bile duct and gallbladder cancer."},{"id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","route":"/people/robin-kate-kelley/","tldr":"San Francisco oncologist who was lead author of KEYNOTE-966, which showed that adding pembrolizumab to gemcitabine and cisplatin helps people with advanced bile duct cancer live longer."},{"id":"angela-lamarca","kind":"person","name":"Angela Lamarca","route":"/people/angela-lamarca/","tldr":"Oncologist who was lead author of ABC-06, the first randomised trial to show that second-line chemotherapy helps people with advanced bile duct cancer."},{"id":"andrew-zhu","kind":"person","name":"Andrew X. Zhu","route":"/people/andrew-zhu/","tldr":"Oncologist who led REACH-2, the first positive biomarker-selected trial in liver cancer, which established ramucirumab for patients with a high alpha-fetoprotein level."},{"id":"michael-heinrich","kind":"person","name":"Michael C. Heinrich","route":"/people/michael-heinrich/","tldr":"Oregon physician-scientist who showed that the KIT mutation type in a GIST predicts how well imatinib works, discovered PDGFRA mutations in the tumours without KIT mutations, and led NAVIGATOR, which established avapritinib for PDGFRA D842V disease."},{"id":"sebastian-bauer","kind":"person","name":"Sebastian Bauer","route":"/people/sebastian-bauer/","tldr":"German sarcoma specialist who was lead author of INTRIGUE, the trial that compared ripretinib with sunitinib as second-line treatment for GIST."},{"id":"heikki-joensuu","kind":"person","name":"Heikki Joensuu","route":"/people/heikki-joensuu/","tldr":"Finnish oncologist who treated the first GIST patient with imatinib in 2000 and led SSG XVIII, the trial that showed three years of adjuvant imatinib beats one year after surgery for high-risk GIST."},{"id":"herve-dombret","kind":"person","name":"Hervé Dombret","route":"/people/herve-dombret/","tldr":"Paris haematologist who led AZA-AML-001, the trial that showed azacitidine can extend survival for older people with acute myeloid leukaemia who cannot have intensive chemotherapy."},{"id":"francesco-lo-coco","kind":"person","name":"Francesco Lo-Coco","route":"/people/francesco-lo-coco/","tldr":"Italian haematologist who led APL0406, the trial that showed acute promyelocytic leukaemia can be cured with all-trans retinoic acid and arsenic trioxide alone, without chemotherapy."},{"id":"michel-attal","kind":"person","name":"Michel Attal","route":"/people/michel-attal/","tldr":"French haematologist whose trials established autologous stem-cell transplantation for myeloma in the 1990s and, in IFM 2009, showed that transplant still adds benefit in the era of lenalidomide, bortezomib and dexamethasone."},{"id":"jeffrey-lancet","kind":"person","name":"Jeffrey E. Lancet","route":"/people/jeffrey-lancet/","tldr":"Florida leukaemia doctor who led the phase 3 trial of CPX-351, the liposomal form of daunorubicin and cytarabine that lengthened survival for older people with secondary acute myeloid leukaemia."},{"id":"jan-burger","kind":"person","name":"Jan A. Burger","route":"/people/jan-burger/","tldr":"Leukaemia specialist who was lead author of RESONATE-2, the trial that made ibrutinib a first-line treatment for chronic lymphocytic leukaemia in older patients."},{"id":"srdan-verstovsek","kind":"person","name":"Srdan Verstovsek","route":"/people/srdan-verstovsek/","tldr":"Haematologist who led the COMFORT-I trial that established ruxolitinib, the first drug approved for myelofibrosis, and MOMENTUM, which established momelotinib for patients with anaemia."},{"id":"raajit-rampal","kind":"person","name":"Raajit K. Rampal","route":"/people/raajit-rampal/","tldr":"New York haematologist who led MANIFEST-2, the trial testing whether adding the BET inhibitor pelabresib to ruxolitinib helps people with myelofibrosis more than ruxolitinib alone."},{"id":"amer-zeidan","kind":"person","name":"Amer M. Zeidan","route":"/people/amer-zeidan/","tldr":"Yale haematologist who led VERONA, the trial that asked whether adding venetoclax to azacitidine helps people with higher-risk myelodysplastic syndromes, and found it did not lengthen survival."},{"id":"john-leonard","kind":"person","name":"John P. Leonard","route":"/people/john-leonard/","tldr":"New York lymphoma specialist who led AUGMENT, the trial that established lenalidomide plus rituximab as a chemotherapy-free option for relapsed follicular and marginal zone lymphoma."},{"id":"philippe-armand","kind":"person","name":"Philippe Armand","route":"/people/philippe-armand/","tldr":"Boston lymphoma doctor who led KEYNOTE-170, the trial that showed pembrolizumab can control relapsed primary mediastinal B-cell lymphoma, and who helped bring PD-1 blockade to Hodgkin lymphoma."},{"id":"caron-jacobson","kind":"person","name":"Caron A. Jacobson","route":"/people/caron-jacobson/","tldr":"Boston lymphoma doctor who led ZUMA-5, the trial that brought the CAR-T therapy axicabtagene ciloleucel to relapsed follicular lymphoma."},{"id":"miles-prince","kind":"person","name":"H. Miles Prince","route":"/people/miles-prince/","tldr":"Melbourne haematologist who led ALCANZA, the trial that showed brentuximab vedotin beats standard treatment for CD30-expressing cutaneous T-cell lymphoma."},{"id":"youn-kim","kind":"person","name":"Youn H. Kim","route":"/people/youn-kim/","tldr":"Stanford dermatologist who led MAVORIC, the trial that established mogamulizumab for mycosis fungoides and Sézary syndrome after earlier treatment."},{"id":"rashmi-murthy","kind":"person","name":"Rashmi K. Murthy","route":"/people/rashmi-murthy/","tldr":"Houston breast cancer doctor who was lead author of HER2CLIMB, the trial that established tucatinib for HER2-positive breast cancer, including in patients with brain metastases."},{"id":"rupert-bartsch","kind":"person","name":"Rupert Bartsch","route":"/people/rupert-bartsch/","tldr":"Vienna oncologist who led TUXEDO-1, the small trial that showed trastuzumab deruxtecan can shrink active brain metastases from HER2-positive breast cancer."},{"id":"mark-robson","kind":"person","name":"Mark E. Robson","route":"/people/mark-robson/","tldr":"New York breast oncologist and cancer geneticist who led OlympiAD, the trial that made olaparib the first PARP inhibitor approved for BRCA-mutated breast cancer."},{"id":"andrea-decensi","kind":"person","name":"Andrea DeCensi","route":"/people/andrea-decensi/","tldr":"Italian oncologist who led TAM-01, the trial that showed a low dose of tamoxifen halves recurrence after non-invasive breast cancer with fewer side effects than the standard dose."},{"id":"shelley-hwang","kind":"person","name":"E. Shelley Hwang","route":"/people/shelley-hwang/","tldr":"Duke surgeon who led COMET, the trial testing whether women with low-risk DCIS can safely be monitored instead of having surgery straight away."},{"id":"luca-gianni","kind":"person","name":"Luca Gianni","route":"/people/luca-gianni/","tldr":"Milan oncologist who led NeoSphere, the trial that showed adding pertuzumab to trastuzumab and docetaxel before surgery clears more HER2-positive breast cancers, the basis for pertuzumab's neoadjuvant approval."},{"id":"jose-baselga","kind":"person","name":"José Baselga","route":"/people/jose-baselga/","tldr":"Spanish oncologist who helped develop trastuzumab, pertuzumab and everolimus for breast cancer, and was lead author of BOLERO-2, which established everolimus plus exemestane for hormone-receptor-positive disease."},{"id":"paul-chapman","kind":"person","name":"Paul B. Chapman","route":"/people/paul-chapman/","tldr":"New York melanoma doctor who was lead author of BRIM-3, the trial that showed vemurafenib lengthens survival in BRAF-mutant melanoma and launched targeted therapy for the disease."},{"id":"michael-atkins","kind":"person","name":"Michael B. Atkins","route":"/people/michael-atkins/","tldr":"Washington oncologist who led DREAMseq, the trial that showed people with BRAF-mutant melanoma live longer if immunotherapy is given before targeted therapy rather than after."},{"id":"john-kirkwood","kind":"person","name":"John M. Kirkwood","route":"/people/john-kirkwood/","tldr":"Pittsburgh melanoma doctor who ran the interferon trials that were the first adjuvant treatment for high-risk melanoma, and later led CheckMate 76K on adjuvant nivolumab for stage II disease."},{"id":"piotr-rutkowski","kind":"person","name":"Piotr Rutkowski","route":"/people/piotr-rutkowski/","tldr":"Polish surgical oncologist who led the pooled EORTC and SWOG trials showing that imatinib shrinks dermatofibrosarcoma protuberans, a rare skin sarcoma driven by a PDGFB fusion."},{"id":"aleksandar-sekulic","kind":"person","name":"Aleksandar Sekulic","route":"/people/aleksandar-sekulic/","tldr":"Mayo Clinic dermatologist who led ERIVANCE, the trial that established vismodegib, the first Hedgehog pathway inhibitor, for advanced basal cell carcinoma."},{"id":"michael-migden","kind":"person","name":"Michael R. Migden","route":"/people/michael-migden/","tldr":"Houston dermatologist who led the trials that established cemiplimab, the first drug approved for advanced cutaneous squamous-cell carcinoma, and sonidegib for basal cell carcinoma."},{"id":"jean-jacques-grob","kind":"person","name":"Jean-Jacques Grob","route":"/people/jean-jacques-grob/","tldr":"Marseille dermatologist who led KEYNOTE-629, which established pembrolizumab for advanced cutaneous squamous-cell carcinoma, and who has been a senior investigator on many European melanoma trials."},{"id":"danny-rischin","kind":"person","name":"Danny Rischin","route":"/people/danny-rischin/","tldr":"Melbourne oncologist who led C-POST, the trial that showed cemiplimab after surgery and radiotherapy cuts recurrence in high-risk cutaneous squamous-cell carcinoma."},{"id":"neil-gross","kind":"person","name":"Neil D. Gross","route":"/people/neil-gross/","tldr":"Houston surgeon who led the trial showing that giving cemiplimab before surgery can eliminate cutaneous squamous-cell carcinoma in about half of patients, sparing many from extensive operations."},{"id":"ralf-gutzmer","kind":"person","name":"Ralf Gutzmer","route":"/people/ralf-gutzmer/","tldr":"German dermato-oncologist who was lead author of IMspire150, the trial that added atezolizumab to vemurafenib and cobimetinib in BRAF-mutant melanoma."},{"id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","route":"/people/shailender-bhatia/","tldr":"Seattle oncologist who led STAMP, the trial that showed pembrolizumab after surgery reduces recurrence of Merkel cell carcinoma, a rare and aggressive skin cancer."},{"id":"robert-ferris","kind":"person","name":"Robert L. Ferris","route":"/people/robert-ferris/","tldr":"Surgeon and immunologist who led CheckMate 141, the trial that made nivolumab the first drug to lengthen survival in head and neck cancer after platinum failure, and E3311 on transoral surgery for HPV-positive throat cancer."},{"id":"joel-guigay","kind":"person","name":"Joël Guigay","route":"/people/joel-guigay/","tldr":"Nice oncologist who led TPExtreme, the GORTEC trial that showed the shorter TPEx regimen is a reasonable alternative to EXTREME for recurrent or metastatic head and neck cancer."},{"id":"jean-pascal-machiels","kind":"person","name":"Jean-Pascal Machiels","route":"/people/jean-pascal-machiels/","tldr":"Brussels oncologist who led KEYNOTE-412, the trial that tested adding pembrolizumab to chemoradiotherapy for locally advanced head and neck cancer."},{"id":"anthony-nichols","kind":"person","name":"Anthony C. Nichols","route":"/people/anthony-nichols/","tldr":"Canadian surgeon who led ORATOR, the first randomised trial to compare robotic surgery with radiotherapy for early throat cancer, which found swallowing was slightly better after radiotherapy."},{"id":"rossella-elisei","kind":"person","name":"Rossella Elisei","route":"/people/rossella-elisei/","tldr":"Pisa endocrinologist who led EXAM, the trial that established cabozantinib for progressive medullary thyroid cancer, and who has studied RET mutations in the disease for decades."},{"id":"samuel-wells","kind":"person","name":"Samuel A. Wells Jr.","route":"/people/samuel-wells/","tldr":"American surgeon who pioneered removing the thyroid in children with inherited RET mutations before cancer develops, led ZETA, the trial that established vandetanib for medullary thyroid cancer, and chaired the American Thyroid Association guideline for the disease."},{"id":"julien-hadoux","kind":"person","name":"Julien Hadoux","route":"/people/julien-hadoux/","tldr":"Paris endocrine oncologist who was lead author of LIBRETTO-531, the trial that showed the selective RET inhibitor selpercatinib beats older kinase inhibitors as first treatment for advanced medullary thyroid cancer."},{"id":"vivek-subbiah","kind":"person","name":"Vivek Subbiah","route":"/people/vivek-subbiah/","tldr":"Early-phase trialist who led the study showing dabrafenib and trametinib work in BRAF-mutant anaplastic thyroid cancer, the first approved treatment for that disease, and many of the RET inhibitor trials."},{"id":"stephen-freedland","kind":"person","name":"Stephen J. Freedland","route":"/people/stephen-freedland/","tldr":"Los Angeles urologist who was lead author of EMBARK, the trial that established enzalutamide for men whose prostate cancer is returning fast after surgery or radiotherapy."},{"id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","tldr":"London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises."},{"id":"gerhardt-attard","kind":"person","name":"Gerhardt Attard","route":"/people/gerhardt-attard/","tldr":"London oncologist who helped develop abiraterone and led the STAMPEDE analysis showing that two years of abiraterone alongside hormone therapy and radiotherapy improves survival in high-risk localised prostate cancer."},{"id":"david-dearnaley","kind":"person","name":"David Dearnaley","route":"/people/david-dearnaley/","tldr":"British radiation oncologist who led CHHiP, the trial that showed prostate cancer can be treated in 20 radiotherapy sessions rather than 37 with the same results, changing practice worldwide."},{"id":"fred-saad","kind":"person","name":"Fred Saad","route":"/people/fred-saad/","tldr":"Montreal urologist who led the zoledronic acid trials in prostate cancer bone metastases and was lead author of ARANOTE, which established darolutamide plus hormone therapy for metastatic hormone-sensitive disease."},{"id":"stephen-boorjian","kind":"person","name":"Stephen A. Boorjian","route":"/people/stephen-boorjian/","tldr":"Mayo Clinic urologist who led the trial of nadofaragene firadenovec, the first gene therapy approved for bladder cancer that no longer responds to BCG."},{"id":"krishnansu-tewari","kind":"person","name":"Krishnansu S. Tewari","route":"/people/krishnansu-tewari/","tldr":"California gynaecologic oncologist who led GOG 240, the trial that made bevacizumab the first targeted drug to lengthen survival in advanced cervical cancer, and EMPOWER-Cervical 1, which did the same for the PD-1 antibody cemiplimab."},{"id":"david-gershenson","kind":"person","name":"David M. Gershenson","route":"/people/david-gershenson/","tldr":"Houston gynaecologic oncologist who defined low-grade serous ovarian cancer as a distinct disease and led GOG 281, the trial that showed the MEK inhibitor trametinib works better than standard treatments for it."},{"id":"vicky-makker","kind":"person","name":"Vicky Makker","route":"/people/vicky-makker/","tldr":"New York oncologist who led KEYNOTE-775, the trial that established lenvatinib plus pembrolizumab for advanced endometrial cancer after chemotherapy."},{"id":"shannon-westin","kind":"person","name":"Shannon N. Westin","route":"/people/shannon-westin/","tldr":"Houston gynaecologic oncologist who led DUO-E, the trial that added durvalumab, with or without olaparib, to first-line chemotherapy for advanced endometrial cancer."},{"id":"marie-plante","kind":"person","name":"Marie Plante","route":"/people/marie-plante/","tldr":"Quebec surgeon who pioneered fertility-sparing surgery for cervical cancer and led SHAPE, the trial that showed a simple hysterectomy is enough for low-risk early cervical cancer."},{"id":"remi-nout","kind":"person","name":"Remi A. Nout","route":"/people/remi-nout/","tldr":"Dutch radiation oncologist who was lead author of PORTEC-2, the trial that showed vaginal brachytherapy is as good as pelvic radiotherapy for high-intermediate-risk endometrial cancer, with fewer side effects."},{"id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/","tldr":"Barcelona oncologist who led GARNET, the trial that brought dostarlimab to mismatch repair-deficient endometrial cancer, and who has led many trials of new drugs for gynaecological cancers."},{"id":"amanda-fader","kind":"person","name":"Amanda Nickles Fader","route":"/people/amanda-fader/","tldr":"Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer."},{"id":"susana-banerjee","kind":"person","name":"Susana Banerjee","route":"/people/susana-banerjee/","tldr":"London gynaecological oncologist who led RAMP 201, the trial that established the avutometinib and defactinib combination for recurrent KRAS-mutant low-grade serous ovarian cancer."},{"id":"paul-brown","kind":"person","name":"Paul D. Brown","route":"/people/paul-brown/","tldr":"Mayo Clinic radiation oncologist whose trials showed that focused radiosurgery preserves thinking and memory better than whole-brain radiotherapy for brain metastases, and that sparing the hippocampus reduces cognitive harm when whole-brain treatment is needed."},{"id":"jan-buckner","kind":"person","name":"Jan C. Buckner","route":"/people/jan-buckner/","tldr":"Mayo Clinic neuro-oncologist who was lead author of the long-term RTOG 9802 results, which showed that adding PCV chemotherapy to radiotherapy roughly doubles survival in high-risk low-grade glioma."},{"id":"eric-jonasch","kind":"person","name":"Eric Jonasch","route":"/people/eric-jonasch/","tldr":"Houston oncologist who led the trial that established belzutifan, the first drug for the tumours of von Hippel-Lindau disease, including kidney cancers, pancreatic tumours and haemangioblastomas."},{"id":"scott-plotkin","kind":"person","name":"Scott R. Plotkin","route":"/people/scott-plotkin/","tldr":"Boston neuro-oncologist who showed that bevacizumab can shrink vestibular schwannomas and restore hearing in people with neurofibromatosis type 2."},{"id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","route":"/people/andrew-lassman/","tldr":"New York neuro-oncologist who led INTELLANCE-1, the trial that tested the EGFR-directed antibody-drug conjugate depatuxizumab mafodotin in newly diagnosed glioblastoma and found it did not extend survival."},{"id":"olivier-chinot","kind":"person","name":"Olivier L. Chinot","route":"/people/olivier-chinot/","tldr":"Marseille neuro-oncologist who was lead author of AVAglio, the trial that showed adding bevacizumab to standard glioblastoma treatment delays progression but does not lengthen life."},{"id":"jacques-grill","kind":"person","name":"Jacques Grill","route":"/people/jacques-grill/","tldr":"Paris paediatric neuro-oncologist who led HERBY, the trial that showed adding bevacizumab does not help children with high-grade glioma, and who leads European trials in diffuse midline glioma."},{"id":"darren-hargrave","kind":"person","name":"Darren R. Hargrave","route":"/people/darren-hargrave/","tldr":"London paediatric neuro-oncologist who led the trial showing that dabrafenib and trametinib work in children with BRAF V600-mutant high-grade glioma."},{"id":"giles-robinson","kind":"person","name":"Giles W. Robinson","route":"/people/giles-robinson/","tldr":"Memphis paediatric neuro-oncologist who led the study showing that the Hedgehog inhibitor vismodegib helps only adults and older children whose medulloblastoma belongs to the SHH subgroup, an early example of subgroup-directed brain tumour therapy."},{"id":"sarah-leary","kind":"person","name":"Sarah E. S. Leary","route":"/people/sarah-leary/","tldr":"Seattle paediatric neuro-oncologist who led COG ACNS0332, the trial that found adding carboplatin to radiotherapy improves survival in children with high-risk group 3 medulloblastoma but isotretinoin does not help."},{"id":"kimberly-dunsmore","kind":"person","name":"Kimberly P. Dunsmore","route":"/people/kimberly-dunsmore/","tldr":"Paediatric oncologist who chaired COG AALL0434, the largest trial ever run in childhood T-cell leukaemia, which showed that adding nelarabine improves disease-free survival."},{"id":"rob-pieters","kind":"person","name":"Rob Pieters","route":"/people/rob-pieters/","tldr":"Dutch paediatric oncologist who led the international Interfant trials for babies with leukaemia and helped create the Princess Máxima Center, which brought all Dutch childhood cancer care into one hospital."},{"id":"inge-van-der-sluis","kind":"person","name":"Inge M. van der Sluis","route":"/people/inge-van-der-sluis/","tldr":"Dutch paediatric oncologist who led the study showing that adding one course of blinatumomab to chemotherapy sharply improves survival for babies with KMT2A-rearranged leukaemia."},{"id":"sylvie-bonvalot","kind":"person","name":"Sylvie Bonvalot","route":"/people/sylvie-bonvalot/","tldr":"Paris surgeon who championed compartmental resection for retroperitoneal sarcoma and led STRASS, the trial that showed preoperative radiotherapy does not improve abdominal recurrence-free survival overall."},{"id":"andrew-wagner","kind":"person","name":"Andrew J. Wagner","route":"/people/andrew-wagner/","tldr":"Boston sarcoma doctor who first showed that mTOR inhibitors shrink perivascular epithelioid cell tumours and then led AMPECT, the trial that made nab-sirolimus the first approved treatment for these rare cancers."},{"id":"patricia-pautier","kind":"person","name":"Patricia Pautier","route":"/people/patricia-pautier/","tldr":"Paris oncologist who led LMS-04, the trial that showed doxorubicin plus trabectedin lengthens survival in advanced leiomyosarcoma compared with doxorubicin alone."},{"id":"patrick-schoffski","kind":"person","name":"Patrick Schöffski","route":"/people/patrick-schoffski/","tldr":"Leuven oncologist who led the trial that showed eribulin lengthens survival in advanced liposarcoma, the basis of the drug's approval for that disease."},{"id":"alice-chen","kind":"person","name":"Alice P. Chen","route":"/people/alice-chen/","tldr":"NCI oncologist who led the trial that showed atezolizumab produces lasting responses in alveolar soft part sarcoma, the first approved treatment for this rare cancer."},{"id":"antoine-italiano","kind":"person","name":"Antoine Italiano","route":"/people/antoine-italiano/","tldr":"Bordeaux oncologist who led CABONE, the trial that showed cabozantinib shrinks or stabilises osteosarcoma and Ewing sarcoma after standard treatment has failed."},{"id":"florence-duffaud","kind":"person","name":"Florence Duffaud","route":"/people/florence-duffaud/","tldr":"Marseille oncologist who led REGOBONE, the trial that showed regorafenib delays progression in metastatic osteosarcoma and other bone sarcomas."},{"id":"robin-jones","kind":"person","name":"Robin L. Jones","route":"/people/robin-jones/","tldr":"London sarcoma specialist who led TAPPAS, the trial that tested the anti-angiogenic protein TRC105 with pazopanib in angiosarcoma, and who has led many international sarcoma trials."},{"id":"jennifer-chan","kind":"person","name":"Jennifer A. Chan","route":"/people/jennifer-chan/","tldr":"Boston oncologist who led CABINET, the trial that showed cabozantinib delays progression of advanced neuroendocrine tumours after other treatments have failed."},{"id":"john-strickler","kind":"person","name":"John H. Strickler","route":"/people/john-strickler/","tldr":"Duke oncologist who led MOUNTAINEER, the trial that made tucatinib plus trastuzumab the first approved HER2-directed treatment for colorectal cancer."},{"id":"andrea-sartore-bianchi","kind":"person","name":"Andrea Sartore-Bianchi","route":"/people/andrea-sartore-bianchi/","tldr":"Milan oncologist who was lead author of HERACLES, the first trial to show that HER2-targeted drugs work in HER2-amplified colorectal cancer."},{"id":"salvatore-siena","kind":"person","name":"Salvatore Siena","route":"/people/salvatore-siena/","tldr":"Milan oncologist who co-led HERACLES and was lead author of DESTINY-CRC01, which showed trastuzumab deruxtecan is active in HER2-positive colorectal cancer, and a leader of the anti-EGFR antibody trials in the disease."},{"id":"rona-yaeger","kind":"person","name":"Rona Yaeger","route":"/people/rona-yaeger/","tldr":"New York oncologist who was lead author of the KRYSTAL-1 colorectal report, which showed adagrasib with cetuximab shrinks KRAS G12C-mutant colorectal cancer and led to the combination's approval."},{"id":"gerald-prager","kind":"person","name":"Gerald W. Prager","route":"/people/gerald-prager/","tldr":"Vienna oncologist who was lead author of SUNLIGHT, the trial that showed adding bevacizumab to trifluridine-tipiracil lengthens survival in refractory colorectal cancer."},{"id":"quincy-chu","kind":"person","name":"Quincy Chu","route":"/people/quincy-chu/","tldr":"Edmonton oncologist who was lead author of KEYNOTE-483 (CCTG IND.227), the trial that showed adding pembrolizumab to chemotherapy lengthens survival in pleural mesothelioma."},{"id":"maria-de-santis","kind":"person","name":"Maria De Santis","route":"/people/maria-de-santis/","tldr":"Berlin oncologist who led SEMPET, the study showing that a PET scan can tell which residual masses after chemotherapy for seminoma still contain cancer, sparing many men further treatment."},{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","route":"/people/sant-chawla/","tldr":"The Santa Monica medical oncologist whose sarcoma practice has run many of the field's early and late phase drug trials, including the aldoxorubicin programme."}]}